Phase II clinical trial of a vas deferens injectable contraceptive for the male

SK Guha, G Singh, S Ansari, S Kumar, A Srivastava… - Contraception, 1997 - Elsevier
Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens
injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride
(SMA) in a solvent vehicle of dimethylsulphoxide (DMSO), a study to assess the
contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and
implemented. Male subjects and their wives with normal reproductive profiles were the
volunteer subjects. The wives were not using any contraceptives. The results reconfirm the …